Compare Global X Copper Miners ETF (COPX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Moderna, Inc. — how do they compare? Global X Copper Miners ETF trades at $84.5 (market cap $7.10B), while Moderna, Inc. trades at $197.42 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 11.1× Global X Copper Miners ETF's market cap, and Moderna, Inc. is trading nearer its 52-week high, Global X Copper Miners ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 50 Days and Moderna, Inc. for 59 Days on average.
| COPX | MRNA | |
|---|---|---|
Market Cap | $7.10B | $78.65B |
Volume | 2,871,128 | 37,373,437 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $203.46 |
52-Week Low | $57.43 | $22.36 |
Typical Hold Time | 50 Days | 59 Days |
Enterprise Value | — | $74.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $83.58, down 3.13% amid bearish technical signals with 15 sell indicators versus 2 buy signals. The ETF faces pressure despite positive copper market fundamentals, with copper prices reaching all-time highs near $6.85 per pound. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though mining equities have underperformed the underlying metal.
The copper shortage narrative supports long-term growth potential, but near-term headwinds include global surplus projections and Federal Reserve policy concerns. COPX offers leveraged exposure to copper prices, with analysts divided between buying dips and cautious holding patterns given valuation concerns and mining operational challenges.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
